{
    "nctId": "NCT02855775",
    "briefTitle": "Monoclonal Antibodies Elimination in Breast Cancer Patient",
    "officialTitle": "Study of the Relative Impact of the Neonatal Fc Receptor (FcRn) and the Therapeutic History on Monoclonal Antibodies Elimination. Proof of the Concept on Patients Treated by Bevacizumab or Trastuzumab in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 76,
    "primaryOutcomeMeasure": "clearance of the bevacizumab",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* A diagnosed cancer\n* patient treated by bevacizumab or trastuzumab\n* Life expectancy of at least 3 months\n* For the women: menopausal women for at least 24 months, sterilized surgically, or, for the women old enough to procreate, use a method of effective contraception (oral contraceptives, contraceptive injections, intra-uterine devices, method of the double barrier, the contraceptive patches). This contraception will have to be pursued during 6 months after the end of the treatment by bevacizumab or by trastuzumab.\n\nExclusion Criteria:\n\n* For Patients treated by trastuzumab: Dyspnoea of severe rest in touch with complications due to the disease or requiring an oxygen therapy.\n* Hypocalcemia severe untreated",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}